Short-term tolvaptan increases water intake and effectively decreases urinary calcium oxalate, calcium phosphate and uric acid supersaturations

Wisit Cheungpasitporn, Stephen B. Erickson, Andrew D Rule, Felicity T Enders, John C Lieske

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose Some patients cannot effectively increase water intake and urine volume to prevent urinary stones. Tolvaptan, a V2 receptor antagonist, blocks water reabsorption in the collecting duct and should decrease urinary supersaturation of stone forming solutes, although this action has never been proved. Materials and Methods We conducted a double-blind, randomized, placebo controlled, crossover study of 21 calcium urinary stone formers stratified into majority calcium oxalate (10 patients) and calcium phosphate (11) groups. Patients received 45 mg tolvaptan per day or placebo for 1 week, followed by a washout week and crossover to tolvaptan or placebo for week 3. A 24-hour urine sample was collected at the end of weeks 1 and 3. Results Tolvaptan vs placebo decreased urinary osmolality (mean ± SD 204 ± 96 vs 529 ± 213 mOsm/kg, p 0.05 for all interactions). Conclusions Tolvaptan increases urine volume and decreases urinary supersaturation in calcium stone formers. Further study is needed to determine if long-term use of V2 receptor antagonists results in fewer stone events.

Original languageEnglish (US)
Pages (from-to)1476-1481
Number of pages6
JournalJournal of Urology
Volume195
Issue number5
DOIs
StatePublished - May 1 2016

Fingerprint

Calcium Oxalate
Uric Acid
Drinking
Urinary Calculi
Placebos
Vasopressin Receptors
Urine
Calcium
Osmolar Concentration
Cross-Over Studies
tolvaptan
calcium phosphate
Water

Keywords

  • kidney calculi
  • osmolar concentration
  • vasopressins
  • water-electrolyte balance

ASJC Scopus subject areas

  • Urology

Cite this

Short-term tolvaptan increases water intake and effectively decreases urinary calcium oxalate, calcium phosphate and uric acid supersaturations. / Cheungpasitporn, Wisit; Erickson, Stephen B.; Rule, Andrew D; Enders, Felicity T; Lieske, John C.

In: Journal of Urology, Vol. 195, No. 5, 01.05.2016, p. 1476-1481.

Research output: Contribution to journalArticle

@article{cea96a1544774c4a98018f1f1883303d,
title = "Short-term tolvaptan increases water intake and effectively decreases urinary calcium oxalate, calcium phosphate and uric acid supersaturations",
abstract = "Purpose Some patients cannot effectively increase water intake and urine volume to prevent urinary stones. Tolvaptan, a V2 receptor antagonist, blocks water reabsorption in the collecting duct and should decrease urinary supersaturation of stone forming solutes, although this action has never been proved. Materials and Methods We conducted a double-blind, randomized, placebo controlled, crossover study of 21 calcium urinary stone formers stratified into majority calcium oxalate (10 patients) and calcium phosphate (11) groups. Patients received 45 mg tolvaptan per day or placebo for 1 week, followed by a washout week and crossover to tolvaptan or placebo for week 3. A 24-hour urine sample was collected at the end of weeks 1 and 3. Results Tolvaptan vs placebo decreased urinary osmolality (mean ± SD 204 ± 96 vs 529 ± 213 mOsm/kg, p 0.05 for all interactions). Conclusions Tolvaptan increases urine volume and decreases urinary supersaturation in calcium stone formers. Further study is needed to determine if long-term use of V2 receptor antagonists results in fewer stone events.",
keywords = "kidney calculi, osmolar concentration, vasopressins, water-electrolyte balance",
author = "Wisit Cheungpasitporn and Erickson, {Stephen B.} and Rule, {Andrew D} and Enders, {Felicity T} and Lieske, {John C}",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.juro.2015.11.027",
language = "English (US)",
volume = "195",
pages = "1476--1481",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Short-term tolvaptan increases water intake and effectively decreases urinary calcium oxalate, calcium phosphate and uric acid supersaturations

AU - Cheungpasitporn, Wisit

AU - Erickson, Stephen B.

AU - Rule, Andrew D

AU - Enders, Felicity T

AU - Lieske, John C

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Purpose Some patients cannot effectively increase water intake and urine volume to prevent urinary stones. Tolvaptan, a V2 receptor antagonist, blocks water reabsorption in the collecting duct and should decrease urinary supersaturation of stone forming solutes, although this action has never been proved. Materials and Methods We conducted a double-blind, randomized, placebo controlled, crossover study of 21 calcium urinary stone formers stratified into majority calcium oxalate (10 patients) and calcium phosphate (11) groups. Patients received 45 mg tolvaptan per day or placebo for 1 week, followed by a washout week and crossover to tolvaptan or placebo for week 3. A 24-hour urine sample was collected at the end of weeks 1 and 3. Results Tolvaptan vs placebo decreased urinary osmolality (mean ± SD 204 ± 96 vs 529 ± 213 mOsm/kg, p 0.05 for all interactions). Conclusions Tolvaptan increases urine volume and decreases urinary supersaturation in calcium stone formers. Further study is needed to determine if long-term use of V2 receptor antagonists results in fewer stone events.

AB - Purpose Some patients cannot effectively increase water intake and urine volume to prevent urinary stones. Tolvaptan, a V2 receptor antagonist, blocks water reabsorption in the collecting duct and should decrease urinary supersaturation of stone forming solutes, although this action has never been proved. Materials and Methods We conducted a double-blind, randomized, placebo controlled, crossover study of 21 calcium urinary stone formers stratified into majority calcium oxalate (10 patients) and calcium phosphate (11) groups. Patients received 45 mg tolvaptan per day or placebo for 1 week, followed by a washout week and crossover to tolvaptan or placebo for week 3. A 24-hour urine sample was collected at the end of weeks 1 and 3. Results Tolvaptan vs placebo decreased urinary osmolality (mean ± SD 204 ± 96 vs 529 ± 213 mOsm/kg, p 0.05 for all interactions). Conclusions Tolvaptan increases urine volume and decreases urinary supersaturation in calcium stone formers. Further study is needed to determine if long-term use of V2 receptor antagonists results in fewer stone events.

KW - kidney calculi

KW - osmolar concentration

KW - vasopressins

KW - water-electrolyte balance

UR - http://www.scopus.com/inward/record.url?scp=84962251783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962251783&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2015.11.027

DO - 10.1016/j.juro.2015.11.027

M3 - Article

C2 - 26598423

AN - SCOPUS:84962251783

VL - 195

SP - 1476

EP - 1481

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -